GRAIL

Products

Category

Product

Brand

Description

Multi-Cancer Diagnostic Tests (MDS101A)

Galleri test

The Galleri test screens blood samples for cfDNA and identifies whether they come from healthy or cancerous cells. It can detect a signal shared by over 50 types of cancer with 99.5% specificity. Galleri is currently offered as LDT and received a breakthrough device designation with the FDA.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.